{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:08Z","timestamp":1789549328244,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11739-026-04403-0","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:00:08Z","timestamp":1779872408000},"page":"2001-2013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CGRP-targeted therapies for migraine and the risk of infection"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-7866","authenticated-orcid":false,"given":"Claudio","family":"Tana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wells-Gatnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Moffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"11","key":"4403_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954\u2013976","journal-title":"Lancet Neurol"},{"issue":"1","key":"4403_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01712-7","volume":"25","author":"C Tana","year":"2024","unstructured":"Tana C, Raffaelli B, Souza MNP, de la Torre ER, Massi DG, Kisani N, Garc\u00eda-Azor\u00edn D, Waliszewska-Pros\u00f3\u0142 M (2024) Health equity, care access and quality in headache: part 1. J Headache Pain 25(1):12","journal-title":"J Headache Pain"},{"issue":"1","key":"4403_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01925-w","volume":"25","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Garcia-Azorin D, Rubio-Beltr\u00e1n E, Ha WS, Messina R, Ornello R, Petrusic I, Raffaelli B, Labastida-Ramirez A, Ruscheweyh R, Tana C, Vuralli D, Waliszewska-Pros\u00f3\u0142 M, Wang W, Wells-Gatnik W (2024) Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain 25(1):214","journal-title":"J Headache Pain"},{"issue":"25","key":"4403_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2174\/1381612829666230821092238","volume":"29","author":"C Tana","year":"2023","unstructured":"Tana C, Cipollone F, Giamberardino MA (2023) New therapeutic options for migraine. Curr Pharm Des 29(25):1964\u20131966","journal-title":"Curr Pharm Des"},{"issue":"10","key":"4403_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231206162","volume":"43","author":"K Aleksovska","year":"2023","unstructured":"Aleksovska K, Hershey AD, Deen M, Icco R, Lee MJ, Diener HC (2023) Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society. Cephalalgia 43(10):3331024231206162","journal-title":"Cephalalgia"},{"issue":"3","key":"4403_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030711","volume":"20","author":"S Afroz","year":"2019","unstructured":"Afroz S, Arakaki R, Iwasa T, Oshima M, Hosoki M, Inoue M, Baba O, Okayama Y, Matsuka Y (2019) CGRP induces differential regulation of cytokines from satellite glial cells in Trigeminal Ganglia and orofacial nociception. Int J Mol Sci 20(3):711","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4403_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02681-6","volume":"19","author":"MB Assas","year":"2021","unstructured":"Assas MB (2021) Anti-migraine agents from an immunological point of view. J Transl Med 19(1):23","journal-title":"J Transl Med"},{"issue":"18","key":"4403_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813979","volume":"24","author":"A Bonura","year":"2023","unstructured":"Bonura A, Brunelli N, Marcosano M et al (2023) Calcitonin gene-related peptide systemic effects: embracing the complexity of its biological roles\u2014a narrative review. Int J Mol Sci 24(18):13979","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4403_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644","journal-title":"Physiol Rev"},{"issue":"20","key":"4403_CR10","doi-asserted-by":"publisher","first-page":"12246","DOI":"10.3390\/ijms232012246","volume":"23","author":"AA Zarban","year":"2022","unstructured":"Zarban AA, Chaudhry H, de Sousa VJ et al (2022) Elucidating the ability of CGRP to modulate microvascular events in mouse skin. Int J Mol Sci 23(20):12246","journal-title":"Int J Mol Sci"},{"issue":"17","key":"4403_CR11","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.3390\/ijms21176005","volume":"21","author":"S Afroz","year":"2020","unstructured":"Afroz S, Arakaki R, Iwasa T et al (2020) Role of CGRP in neuroimmune interaction via NF-\u03baB signaling genes in glial cells of trigeminal ganglia. Int J Mol Sci 21(17):6005","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4403_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00726-011-1161-2","volume":"45","author":"B Holzmann","year":"2013","unstructured":"Holzmann B (2013) Modulation of immune responses by the neuropeptide CGRP. Amino Acids 45(1):1\u20137","journal-title":"Amino Acids"},{"issue":"4","key":"4403_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2174\/13892037113149990046","volume":"14","author":"B Holzmann","year":"2013","unstructured":"Holzmann B (2013) Antiinflammatory activities of CGRP modulating innate immune responses in health and disease. Curr Protein Pept Sci 14(4):268\u2013274","journal-title":"Curr Protein Pept Sci"},{"issue":"1","key":"4403_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4049\/jimmunol.179.1.607","volume":"179","author":"MD Harzenetter","year":"2007","unstructured":"Harzenetter MD, Novotny AR, Gais P et al (2007) Negative regulation of tlr responses by the neuropeptide CGRP is mediated by the transcriptional repressor ICER. J Immunol 179(1):607\u2013615","journal-title":"J Immunol"},{"issue":"4","key":"4403_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.immuni.2019.09.005","volume":"51","author":"A Wallrapp","year":"2019","unstructured":"Wallrapp A, Burkett PR, Riesenfeld SJ et al (2019) Calcitonin gene-related peptide negatively regulates alarmin-driven type 2 innate lymphoid cell responses. Immunity 51(4):709-723.e6","journal-title":"Immunity"},{"issue":"3","key":"4403_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4049\/jimmunol.2100139","volume":"208","author":"W Ding","year":"2022","unstructured":"Ding W, Stohl LL, Saab J et al (2022) Regulation of cutaneous immunity in vivo by calcitonin gene-related peptide signaling through endothelial cells. J Immunol 208(3):633\u2013641","journal-title":"J Immunol"},{"issue":"3","key":"4403_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/apha.12442","volume":"213","author":"RD Granstein","year":"2015","unstructured":"Granstein RD, Wagner JA, Stohl LL, Ding W (2015) Calcitonin gene-related peptide: key regulator of cutaneous immunity. Acta Physiol (Oxf) 213(3):586\u2013594","journal-title":"Acta Physiol (Oxf)"},{"issue":"11","key":"4403_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322574121","volume":"121","author":"W Kulalert","year":"2024","unstructured":"Kulalert W, Wells AC, Link VM et al (2024) The neuroimmune CGRP\u2013RAMP1 axis tunes cutaneous adaptive immunity to the microbiota. Proc Natl Acad Sci U S A 121(11):e2322574121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4403_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/infdis\/jiad358","volume":"229","author":"Y Li","year":"2024","unstructured":"Li Y, Wang L, Gao Z et al (2024) Neuropeptide CGRP promotes immune homeostasis of bacterial meningitis by inducing MHC class II ubiquitination. J Infect Dis 229(3):855\u2013865","journal-title":"J Infect Dis"},{"issue":"3","key":"4403_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41423-022-00968-w","volume":"20","author":"F Zhu","year":"2023","unstructured":"Zhu F, Yu D, Qin X et al (2023) The neuropeptide CGRP enters the macrophage cytosol to suppress the NLRP3 inflammasome during pulmonary infection. Cell Mol Immunol 20(3):264\u2013276","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"4403_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/14728214.2023.2288334","volume":"28","author":"C Tana","year":"2023","unstructured":"Tana C, Cipollone F, Giamberardino MA, Martelletti P (2023) New drugs targeting calcitonin gene-related peptide for the management of migraines. Expert Opin Emerg Drugs 28(4):233\u2013240","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"4403_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14740338.2021.1866537","volume":"20","author":"L Pellesi","year":"2021","unstructured":"Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirguliyev S, Al-Karagholi MA, Amin FM, Sessa M (2021) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opin Drug Saf 20(4):467\u2013474","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"4403_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000616","volume":"6","author":"S Naghdi","year":"2024","unstructured":"Naghdi S, Underwood M, Brown A, Matharu M, Duncan C, Davies N, Aksentyte A, Mistry H (2024) Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ Neurol Open 6(1):e000616","journal-title":"BMJ Neurol Open"},{"issue":"1","key":"4403_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-025-02040-0","volume":"26","author":"M Straburzy\u0144ski","year":"2025","unstructured":"Straburzy\u0144ski M, Kopyt D, Marschollek K, B\u0142aszczyk B, Kuca-Warnawin E, Kurowska W, Misiak B, Peng KP, Waliszewska-Pros\u00f3\u0142 M, May A (2025) Increased infection risk in patients on preventive CGRP-targeting therapies: a meta-analysis and clinical effect assessment. J Headache Pain 26(1):88","journal-title":"J Headache Pain"},{"issue":"5","key":"4403_CR25","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725","journal-title":"Eur J Neurol"},{"issue":"5","key":"4403_CR26","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD (2020) One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology 95(5):e469\u2013e479","journal-title":"Neurology"},{"issue":"8","key":"4403_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70328","volume":"32","author":"SJ Tepper","year":"2025","unstructured":"Tepper SJ, Dodick DW, Lanteri-Minet M, Dolezil D, Gil-Gouveia R, Lucas C, Piasecka-Stryczynska K, Szab\u00f3 G, Mikol DD, Chehrenama M, Chou DE, Liu Z, da Silva Lima GP (2025) Efficacy and Safety of erenumab in adults with medication overuse headache: final results from a phase 4 randomized placebo-controlled study. Eur J Neurol 32(8):e70328","journal-title":"Eur J Neurol"},{"issue":"11","key":"4403_CR28","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM, Stroud C, Tockhorn-Heidenreich A, Detke HC (2021) Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER trial. Adv Ther 38(11):5465\u20135483","journal-title":"Adv Ther"},{"issue":"1","key":"4403_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s10194-023-01613-1","volume":"24","author":"J Zhou","year":"2023","unstructured":"Zhou J, Zhong L, Chowdhury D, Skorobogatykh K, Luo G, Yang X, Zhang M, Sun L, Liu H, Qian C, Yu S (2023) Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study. J Headache Pain 24(1):103","journal-title":"J Headache Pain"},{"issue":"5","key":"4403_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","volume":"38","author":"P Pozo-Rosich","year":"2022","unstructured":"Pozo-Rosich P, Detke HC, Wang S, Dole\u017eil D, Li LQ, Aurora SK, Reuter U (2022) Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin 38(5):731\u2013742","journal-title":"Curr Med Res Opin"},{"issue":"18","key":"4403_CR31","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, Dodick DW (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95(18):e2487\u2013e2499","journal-title":"Neurology"},{"issue":"1","key":"4403_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126","journal-title":"BMC Neurol"},{"issue":"1","key":"4403_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s10194-023-01688-w","volume":"24","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Gendolla A, Sperling B, Ettrup A, Josiassen MK, Starling AJ (2023) Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. J Headache Pain 24(1):155","journal-title":"J Headache Pain"},{"key":"4403_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/head.15002","author":"D Kudrow","year":"2025","unstructured":"Kudrow D, Croop RS, Thiry A, Lipton RB (2025) A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache 66(2):407\u2013416. doi. https:\/\/doi.org\/10.1111\/head.15002","journal-title":"Headache"},{"issue":"2","key":"4403_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","volume":"40","author":"SD Silberstein","year":"2023","unstructured":"Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A (2023) Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther 40(2):445\u2013459","journal-title":"Adv Ther"},{"key":"4403_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2024","unstructured":"Sun W, Li Y, Xia B, Chen J, Liu Y, Pang J, Liu F, Cheng H (2024) Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. Front Pharmacol 14:1257282","journal-title":"Front Pharmacol"},{"key":"4403_CR37","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/head.14962","volume":"65","author":"V Nikitina","year":"2025","unstructured":"Nikitina V, Santi Laurini G, Montanaro N, Motola D (2025) Postmarketing safety of migraine prophylactic monoclonal antibodies: an EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. Headache 65:1080\u20131094","journal-title":"Headache"},{"issue":"1","key":"4403_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09490-1","volume":"15","author":"J Chen","year":"2025","unstructured":"Chen J, Huang S, Chen Y, Luo C, Li Y (2025) Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment. Sci Rep 15(1):24491","journal-title":"Sci Rep"},{"key":"4403_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1431562","volume":"15","author":"Q Liang","year":"2024","unstructured":"Liang Q, Liao X, Wu H, Huang Y, Liang T, Li H (2024) Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s adverse event reporting system databases. Front Pharmacol 15:1431562","journal-title":"Front Pharmacol"},{"issue":"1","key":"4403_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s10194-024-01858-4","volume":"25","author":"JL Hu","year":"2024","unstructured":"Hu JL, Wu JY, Xu S, Qian SY, Jiang C, Zheng GQ (2024) Post-marketing safety concerns with rimegepant based on a pharmacovigilance study. J Headache Pain 25(1):169","journal-title":"J Headache Pain"},{"issue":"8","key":"4403_CR41","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s11739-021-02787-9","volume":"16","author":"LF Iannone","year":"2021","unstructured":"Iannone LF, Geppetti P, Chiarugi A, De Cesaris F (2021) COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report. Intern Emerg Med 16(8):2309\u20132311","journal-title":"Intern Emerg Med"},{"issue":"15","key":"4403_CR42","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098\u20131104","journal-title":"N Engl J Med"},{"issue":"3","key":"4403_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/myc.70040","volume":"68","author":"LSdeP Barbosa","year":"2025","unstructured":"Barbosa LSdeP, Ely MM, Salom\u00e9 TM, de Almeida Souza GH, Santos DA, Bastos RW, Rossato L (2025) Fungal infections associated with TNF-inhibitors: a 20-year of a systematic review fungal infections and TNF-inhibitors. Mycoses 68(3):e70040","journal-title":"Mycoses"},{"key":"4403_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S28801","volume":"5","author":"T Ali","year":"2013","unstructured":"Ali T, Bronze M, Kaitha S, Mahmood S, Ftesi A, Stone J (2013) Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 5:79","journal-title":"Drug Healthc Patient Saf"},{"issue":"3","key":"4403_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/CMR.00035-19","volume":"33","author":"JS Davis","year":"2020","unstructured":"Davis JS, Ferreira D, Paige E, Gedye C, Boyle M (2020) Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev 33(3):10\u2013128","journal-title":"Clin Microbiol Rev"},{"key":"4403_CR46","first-page":"13","volume":"26","author":"T Koga","year":"2022","unstructured":"Koga T, Kawakami A (2022) Interleukin-6 inhibition in the treatment of autoinflammatory diseases. Front Immunol 26:13","journal-title":"Front Immunol"},{"issue":"4","key":"4403_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13(4):234\u2013243 (2)","journal-title":"Nat Rev Rheumatol"},{"issue":"49","key":"4403_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036450","volume":"102","author":"MM Cipolat","year":"2023","unstructured":"Cipolat MM, Rodrigues DRR, Brenol CV, Pasqualotto AC, Falci DR (2023) Incidence of histoplasmosis in patients receiving TNF-alpha inhibitors: a systematic review and meta-analysis. Medicine (Baltimore) 102(49):e36450\u20130","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"4403_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2217\/imt-2018-0113","volume":"11","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Deng W, Wu Q, Sun L (2019) Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. Immunotherapy 11(4):321\u2013333","journal-title":"Immunotherapy"},{"key":"4403_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100361","volume":"18","author":"YJ Kim","year":"2021","unstructured":"Kim YJ, Granstein RD (2021) Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions. Brain Behav Immun Health 18:100361","journal-title":"Brain Behav Immun Health"},{"issue":"9","key":"4403_CR51","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/head.14390","volume":"62","author":"D Kudrow","year":"2022","unstructured":"Kudrow D, Nguyen L, Semler J, Stroud C, Samaan K, Hoban DB, Wietecha L, Hsu HA, Pearlman E (2022) A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist. Headache 62(9):1164\u20131176","journal-title":"Headache"},{"issue":"1","key":"4403_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01330-7","volume":"22","author":"JC Ray","year":"2021","unstructured":"Ray JC, Allen P, Bacsi A, Bosco JJ, Chen L, Eller M, Kua H, Lim LL, Matharu MS, Monif M, Ruttledge M, Stark RJ, Hutton EJ (2021) Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain 22(1):121","journal-title":"J Headache Pain"},{"issue":"10","key":"4403_CR53","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1474-4422(23)00206-5","volume":"22","author":"SS Hugger","year":"2023","unstructured":"Hugger SS, Do TP, Ashina H, Goicochea MT, Jenkins B, Sacco S, Lee MJ, Brennan KC, Amin FM, Steiner TJ, Ashina M (2023) Migraine in older adults. Lancet Neurol 22(10):934\u2013945","journal-title":"Lancet Neurol"},{"issue":"9","key":"4403_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00128-24","volume":"98","author":"CC Barbosa Bomfim","year":"2024","unstructured":"Barbosa Bomfim CC, G\u00e9nin H, Cottoignies-Callamarte A, Gallois-Montbrun S, Murigneux E, Sams A, Rosenberg AR, Belouzard S, Dubuisson J, Kosminder O, P\u00e8ne F, Terrier B, Bomsel M, Ganor Y (2024) CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients. J Virol 98(9):e0012824","journal-title":"J Virol"},{"issue":"10","key":"4403_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/v14102123","volume":"14","author":"M Rizzi","year":"2022","unstructured":"Rizzi M, Tonello S, Morani F, Rizzi E, Casciaro GF, Matino E, Costanzo M, Zecca E, Croce A, Pedrinelli A, Vassia V, Landi R, Mallela VR, D\u2019Onghia D, Minisini R, Bellan M, Castello LM, Gavelli F, Avanzi GC, Patrucco F, Pirisi M, Colangelo D, Sainaghi PP (2022) CGRP plasma levels correlate with the clinical evolution and prognosis of hospitalized acute COVID-19 patients. Viruses 14(10):2123","journal-title":"Viruses"},{"issue":"3","key":"4403_CR56","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa199","volume":"5","author":"L Ochoa-Callejero","year":"2021","unstructured":"Ochoa-Callejero L, Garc\u00eda-Sanmart\u00edn J, Villoslada-Blanco P, \u00cd\u00f1iguez M, P\u00e9rez-Matute P, Pujadas E, Fowkes ME, Brody R, Oteo JA, Mart\u00ednez A (2021) Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. J Endocr Soc 5(3):bvaa199","journal-title":"J Endocr Soc"},{"issue":"7","key":"4403_CR57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26371","volume":"6","author":"K Wang","year":"2023","unstructured":"Wang K, Fenton BT, Deng Y, Anthony SE, Dao VX, Schindler E, Lipton RB, Guirguis A, Skanderson M, Seng EK, Sico JJ (2023) Calcitonin gene-related peptide monoclonal antibodies and risk of SARS-CoV-2 infection and severe COVID-19 outcomes among veterans with migraine disorder. JAMA Netw Open 6(7):e2326371","journal-title":"JAMA Netw Open"},{"issue":"8","key":"4403_CR58","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.nrl.2021.03.003","volume":"36","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo JV, Alpuente A, Torres-Ferrus M, S\u00e1nchez-Mateo NM, Viguera-Romero J, L\u00f3pez-Veloso AC, L\u00f3pez-Bravo A, Gago-Veiga AB, Irimia Sieira P, Porta-Etessam J, Santos-Lasaosa S, Pozo-Rosich P, Spanish CGRP-COVID Study Group (2021) Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications. Neurologia (Engl Ed) 36(8):611\u2013617","journal-title":"Neurologia (Engl Ed)"},{"issue":"12","key":"4403_CR59","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/17425255.2023.2280221","volume":"19","author":"T Takizawa","year":"2023","unstructured":"Takizawa T, Ihara K, Uno S, Ohtani S, Watanabe N, Imai N, Nakahara J, Hori S, Garcia-Azorin D, Martelletti P (2023) Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review. Expert Opin Drug Metab Toxicol 19(12):951\u2013967","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"4403_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43(3):3331024231152169","journal-title":"Cephalalgia"},{"issue":"1","key":"4403_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01753-y","volume":"25","author":"R Oliveira","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F (2024) CGRP-targeted medication in chronic migraine - systematic review. J Headache Pain 25(1):51","journal-title":"J Headache Pain"},{"issue":"4","key":"4403_CR62","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40264-024-01399-4","volume":"47","author":"EB Cohen","year":"2024","unstructured":"Cohen EB, Regev A, Garg A, Di Bisceglie AM, Lewis JH, Vierling JM, Hey-Hadavi J, Steplewski K, Fettiplace A, Chen CL, Pehlivanov N, Kendrick S, Avigan M I (2024) Consensus guidelines: best practices for the prevention, detection and management of Hepatitis B Virus reactivation in clinical trials with immunosuppressive\/immunomodulatory therapy. Drug Saf 47(4):321\u2013332","journal-title":"Drug Saf"},{"issue":"10483","key":"4403_CR63","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, MaassenVanDenBrink A (2025) Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet 405(10483):1014\u20131026","journal-title":"Lancet"},{"issue":"1","key":"4403_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01637-7","volume":"24","author":"J Schoenen","year":"2023","unstructured":"Schoenen J, Van Dycke A, Versijpt J, Paemeleire K (2023) Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin gene-related peptide pathway: a narrative review. J Headache Pain 24(1):99","journal-title":"J Headache Pain"},{"issue":"4","key":"4403_CR65","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64(4):333\u2013341","journal-title":"Headache"},{"issue":"2","key":"4403_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","volume":"24","author":"AS Wattiez","year":"2020","unstructured":"Wattiez AS, Sowers LP, Russo AF (2020) Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets 24(2):91\u2013100","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"4403_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13177-y","volume":"272","author":"MC Garc\u00eda-Castillo","year":"2025","unstructured":"Garc\u00eda-Castillo MC, Sierra-Menc\u00eda \u00c1, Caronna E, Toledo-Alfocea D, Jaimes A, Urtiaga S, Casas-Lim\u00f3n J, Mu\u00f1oz-Vendrell A, Santos-Lasaosa S, Garc\u00eda Mart\u00edn V, Mart\u00edn \u00c1vila G, Polanco M, Villar-Mart\u00ednez MD, Trevino-Peinado C, Rubio-Flores L, S\u00e1nchez-Soblechero A, Portocarrero S\u00e1nchez L, Luque-Buzo E, Lozano-Ros A, Gago-Veiga AB, D\u00edaz-De-Ter\u00e1n J, Recio Garc\u00eda A, Canales Rodr\u00edguez J, G\u00f3mez Garc\u00eda A, Gonz\u00e1lez Salaices M, Campoy S, M\u00ednguez-Olaondo A, Maniataki S, Gonz\u00e1lez-Quintanilla V, Porta-Etessam J, Cuadrado ML, Guerrero Peral \u00c1L, Pozo-Rosich P, Rodr\u00edguez-Vico J, Huerta-Villanueva M, Pascual J, Goadsby PJ, Gonzalez-Martinez A (2025) Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies. J Neurol 272(6):443","journal-title":"J Neurol"},{"issue":"12","key":"4403_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16450","volume":"31","author":"LF Iannone","year":"2024","unstructured":"Iannone LF, Romozzi M, Russo A, Saporito G, De Santis F, Ornello R, Sances G, Vaghi G, Tassorelli C, Albanese M, Guerzoni S, Casalena A, Vollono C, Calabresi P, Prudenzano MP, Mampreso E, Volta GD, Valente MR, Avino G, Chiarugi A, Sacco S, Pistoia F, Italian Headache Registry (RICe) study group (2024) Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: a multicenter, prospective, cohort study. Eur J Neurol 31(12):e16450","journal-title":"Eur J Neurol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04403-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04403-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04403-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:02:39Z","timestamp":1789545759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04403-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4403"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04403-0","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CT serves as Editor of the Primary Section of Annals of Medicine, and member of the Editorial Board of The Journal of Headache and Pain. BR has served on advisory boards for, consulted for, and\/or been a speaker for Allergan\/AbbVie, Eli Lilly, Novartis, Organon, Perfood, and Teva. She has received research funding from Lundbeck, Novartis, German Migraine and Headache Society, German Research Foundation, and Else Kr\u00f6ner-Fresenius-Stiftung. She is an associate editor of The Journal of Headache and Pain and Cephalalgia. RO reports personal fees from AbbVie, Bayer, Eli Lilly, Lundbeck, Novartis, Organon, Pfizer, and Teva; he is Associate Editor for Arquivos de Neuropsiquiatria and Editorial Board Member for The Journal of Headache and Pain, International Journal of Stroke, and Confinia Cephalalgica. RM reports receiving personal fees from AbbVie, Biomedia, Eli Lilly, Lundbeck, Organon, Pfizer, and Teva, and grants from the Italian Ministry of Health, outside of the submitted work. WWG has no conflicts of interest to report. PM is the Editor in Chief of the Journal of Headache and pain and of SN Comprehensive Clinical Medicine. LM has no conflict of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}